ANI Pharmaceuticals Inc Gets a Buy Rating from Canaccord Genuity

In a report released today, Dewey Steadman from Canaccord Genuity maintained a Buy rating on ANI Pharmaceuticals Inc (NASDAQ: ANIP), with a price target of $82. The company’s shares opened today at $61.11.

According to TipRanks.com, Steadman is ranked 0 out of 5 stars with an average return of -6.5% and a 34.9% success rate. Steadman covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Cardiome Pharma Corp, and Perrigo Company plc.

ANI Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $75.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $74.70 and a one-year low of $42.23. Currently, ANI Pharmaceuticals Inc has an average volume of 113.1K.

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. Most recently, in March 2018, Arthur Przybyl, the President & CEO of ANIP sold 40,000 shares for a total of $2,473,143.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products.